Galvanize, a clinical-stage medical technology company developing Pulsed Electric Field (PEF) therapies for solid tumors and other conditions, has announced the close of a massive $100 million Series C funding round. The raise, led by a syndicate of world-class investors including Sofinnova Partners, Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, Fidelity Management and Research Company, T. Rowe Price, Gilmartin Capital LLC, Intuitive Surgical, and ATP (Apple Tree Partners), positions Galvanize as one of the most well-funded companies in the medtech sector this year.

The round underscores investor conviction in Galvanize’s mission to transform energy into therapy by leveraging PEF systems to achieve durable clinical outcomes without the need for traditional drugs or invasive surgery. Founded by Jonathan Waldstreicher, MD, Galvanize is pioneering a new frontier in medical treatment - one that combines engineering precision with life-saving clinical applications.

A New Era in Tumor Therapy

Galvanize is designing and developing PEF-based systems aimed at addressing significant unmet needs in oncology and beyond. PEF technology delivers controlled, high-intensity electric fields to target cells, disrupting their membranes in a way that leads to cell death or altered biological activity. Unlike chemotherapy or radiation, PEF can be localized, non-thermal, and tissue-specific, reducing collateral damage to healthy tissue.

By applying this approach, Galvanize is seeking to improve treatment options for patients with solid tumors, offering solutions that could dramatically change outcomes for cancer patients worldwide.

Investors Signal a New Category Is Emerging

The sheer scale of this Series C round signals not only confidence in Galvanize’s leadership and technology, but also a broader market validation of bioelectronic and energy-based therapies as a transformative new category in medicine. With participation from both healthcare-focused funds and crossover investors like Fidelity and T. Rowe Price, Galvanize is attracting capital from institutions that typically back companies poised for long-term category leadership.

And here’s the insight founders often overlook: Galvanize didn’t raise $100 million by merely promising a breakthrough - it earned that confidence by positioning itself as the inevitable leader of an entirely new therapeutic category. Startups that try to differentiate within an existing space often get trapped in incrementalism, competing on features or cost. But those that frame themselves as creating the category itself invite investors to dream in multiples, not percentages. For founders, the ultra-value drop is this: don’t just pitch your solution, pitch the inevitability of the category you are building. Investors want to back the company that defines the playbook, not one that tweaks around the edges of an old one.

Leadership Driving Innovation Forward

Under the guidance of Jonathan Waldstreicher, MD, Galvanize has built a team of engineers, clinicians, and regulatory experts who understand the complexities of taking disruptive medtech from lab to market. Waldstreicher’s dual expertise in medicine and innovation has been crucial in bridging scientific rigor with business execution - a blend that investors consistently seek at this stage.

Clinical and Commercial Roadmap

With the fresh $100 million, Galvanize plans to accelerate clinical trials across oncology indications, expand into new therapeutic areas, and prepare for eventual regulatory submissions. A portion of the capital will also be used to scale engineering and manufacturing capabilities, ensuring that Galvanize is ready for commercialization once approvals are secured.

The company is also expected to deepen collaborations with major medical centers and surgical leaders, building a strong clinical evidence base that will be critical in driving adoption and reimbursement.

Why Galvanize Matters

Galvanize’s work goes beyond another medtech milestone - it reflects a shift in how healthcare innovation is evolving. Instead of relying solely on pharmaceuticals or invasive surgery, energy-based therapies like PEF promise a future where precision treatments reduce toxicity, improve patient quality of life, and expand the arsenal physicians can use against devastating diseases.

In the broader context, Galvanize stands as a signal for the medtech community: that bold bets on category creation, backed by deep science and visionary leadership, can unlock capital on a scale that changes the trajectory not just of a company, but of an entire industry.